The U.S. had previously said that the antibody drug from Mapp Biopharmaceutical would only be made available to Americans deemed to be at high risk after exposure to the virus.

Phase 1 trials could begin in July, likely in the UK and possibly Uganda, Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, said in an…

The United States is stepping into a more direct role in the Ebola response in the Democratic Republic of Congo by supplying doses of an experimental...